Menu
October 6, 2023 : Celltrion USA, Inc., a leading biopharmaceutical company, today announced that it has signed a contract with Ventegra®, a major U.S. Medical Benefits Manager (MBM), to add Yuflyma® (adalimumab-aaty) as a preferred formulary product in both public and private insurance markets. This agreement will expand access to Yuflyma®, a biosimilar treatment for various autoimmune conditions, for millions of Americans.
Yuflyma® is a biosimilar to Humira® (adalimumab), the world’s best-selling biologic drug. Biosimilars are highly similar to biologic drugs but are typically more affordable. Yuflyma® is approved by the U.S. Food and Drug Administration (FDA) to treat a variety of autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.
The addition of Yuflyma® to Ventegra’s formulary is a significant development for Celltrion USA and patients who rely on Yuflyma® for treatment. Ventegra administers pharmacy benefits for approximately 3.6% of the entire U.S. population, and other health insurers follow its formulary decisions widely.
“We are excited to partner with Ventegra® to expand access to Yuflyma® for millions of Americans,” said Francine Galante, Vice President of Market Access at Celltrion USA. “Yuflyma® is a safe and effective biosimilar treatment for various autoimmune conditions, and we are committed to making it more affordable and accessible to needy patients.”
“We are pleased to add Yuflyma® to our formulary as a preferred biosimilar option for our members,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “This agreement is a testament to our commitment to providing our members access to high-quality, affordable healthcare.”
The addition of Yuflyma® to Ventegra’s formulary is a significant development for Celltrion USA and patients who rely on Yuflyma® for treatment. This agreement will expand access to Yuflyma®, a biosimilar treatment for various autoimmune conditions, for millions of Americans.
